Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Region Stockholm
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05679024CT.gov Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation | — | Recruiting | — | — | — |
NCT03907046CT.gov Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | — | Recruiting | — | — | — |
NCT03996772CT.gov PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation | — | Completed | — | — | — |
NCT03153150CT.gov Start or STop Anticoagulants Randomised Trial (SoSTART) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intracerebral Hemorrhage
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apixaban (this asset) | Region Stockholm | P3 | B · 63 |
| Edoxaban | Population Health Research Institute | P4 | BBB |
| Tranexamic Acid | Christian Medical College and Hospital, Ludhiana, India | P4 | BB |
| Aspirin | University Hospital, Lille | P4 | BB |
| Rivaroxaban | Imperial College London | P3 | BB |
| Tenecteplase | Gaurav Gupta, MD | P3 | BB |
| Dexmedetomidine | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Midazolam | Henry M. Jackson Foundation for the Advancement of Military Medicine | P4 | BB |
| Lacosamide | University of North Carolina, Chapel Hill | P4 | BB |
+42 more in the Intracerebral Hemorrhage cohort
Other indications for Apixaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | BBB · 79 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Transient Ischemic Attack | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apixaban in Intracerebral Hemorrhage. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apixaban-intracerebral-hemorrhage-20137
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →